AIM ImmunoTech expects Q1 2027 topline data from pancreatic cancer trial

AIM ImmunoTech's Phase 2 DURIPANC study of Ampligen plus durvalumab in metastatic pancreatic cancer expects topline results in Q1 2027. An overall survival analysis is scheduled to begin in Q3 2027.